Analysis of the Efficacy and Prospects for Application of Olorparib and Dabrafenib in Liver Cancer Treatment

Abstract Introduction/Objective To evaluate the effectiveness of Olaparib and Dabrafenib in the treatment of liver cancer and explore their potential prospects for future applications. Methods/Case Report A comprehensive analysis of relevant literature on Olaparib and Dabrafenib in the treatment of liver cancer was conducted, including clinical trials, case studies, and previous meta-analyses. Key indicators such as treatment efficacy, adverse reactions, and patient survival rates were examined. Results (if a Case Study enter NA) In patients treated with the two drugs, the proportion of AFP decreased was 60.24% and 65.87%, the proportion of serum ferritin decreased was 50.25% and 53.39%, the proportion of CT tumor abbreviations was 52.13% and 58.89%, and the effective rate was 38.14% and 40.02%, respectively. There was no significant difference between the two drugs (P > 0.05). Survival analysis showed that the median progression-free survival was 10.7 and 12.3 months, respectively, and the median overall survival was 17.6 and 20.1 months, respectively. The incidence of adverse events including fever, fatigue, chills, nausea and rash was 23.14% and 28.56%, respectively, and there was no significant difference between the two drugs (P > 0.05). Conclusion Olaparib and Dabrafenib demonstrate significant efficacy in the treatment of liver cancer, offering new therapeutic options for patients. The application prospects of these drugs are promising, and they are expected to become crucial components in liver cancer treatment. Further research and clinical practice will contribute to a more comprehensive understanding of their mechanisms of action, optimization of treatment regimens, and improvement of the overall quality of life for liver cancer patients.